NR5A2 and type 1 diabetes mellitus: Given the strong disease‐modifying properties of LRH‐1/NR5A2 activation in mouse models of T1D and aiming to evaluate the potential for clinical applicability of this strategy, herein we expanded our studies to human primary immune cells obtained from individuals with T1D as well as from healthy donors.